Ajaz Afzal, MD
Internal Medicine · Kissimmee, FLNPI 1750341236
Payments from drug & device makers
Across 145 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$463
- GSK$314
- AstraZeneca$232
- Protega Pharmaceutials Inc$209
- Scilex Pharmaceuticals Inc.$198
- Novo Nordisk$166
- plus $934 from 28 others
What the payments were for
- Food & beverage$2,49499%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $463 |
| GSK | 18 | $314 |
| AstraZeneca | 13 | $232 |
| Protega Pharmaceutials Inc | 10 | $209 |
| Scilex Pharmaceuticals Inc. | 14 | $198 |
| Novo Nordisk | 9 | $166 |
| Pfizer | 9 | $153 |
| Amarin Pharma, Inc. | 4 | $70 |
| Johnson & Johnson | 3 | $55 |
| Lilly USA, LLC | 2 | $44 |
| Acadia Pharmaceuticals Inc | 2 | $43 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Gilead | 2 | $38 |
| Amgen(2 entities) | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Evoke Pharma, Inc. | 2 | $34 |
| Indivior Inc. | 2 | $30 |
| Braeburn Inc. | 1 | $27 |
| Mylan Specialty L.p. | 1 | $26 |
| Almatica Pharma LLC | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Orexo US, Inc. | 1 | $21 |
| Merck | 1 | $21 |
| Bayer | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
| Organogenesis Inc. | 1 | $14 |
| Strongbridge US Inc. | 1 | $12 |
How this compares
$2,515 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 211 | $234,804 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 163 | $121,951 |
| OzempicSemaglutide | 103 | $106,040 |
| EliquisApixaban | 89 | $60,659 |
| AirsupraAlbuterol Sulfate/Budesonide | 42 | $54,990 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $50,973 |
| LinzessLinaclotide | 71 | $47,843 |
| TrulicityDulaglutide | 38 | $40,122 |
| JardianceEmpagliflozin | 40 | $33,387 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 153 | $29,610 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $28,962 |
| JanuviaSitagliptin Phosphate | 26 | $28,841 |
| FarxigaDapagliflozin Propanediol | 33 | $27,437 |
| Lidocaine | 208 | $23,851 |
| ZtlidoLidocaine | 30 | $19,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $44 | $274,926249 claims |
| AstraZenecaBreztri Aerosphere, Airsupra, Farxiga, Symbicort | $232 | $212,386268 claims |
| Novo NordiskOzempic | $166 | $106,040103 claims |
| PfizerEliquis | $153 | $60,65989 claims |
| AbbVieLinzess, Restasis | $463 | $57,31585 claims |
| GileadBiktarvy | $38 | $50,97314 claims |
| MerckJanuvia, Janumet | $21 | $35,68837 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $21 | $29,610153 claims |
| GSKTrelegy Ellipta | $314 | $28,96242 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $198 | $19,63330 claims |
| Indivior Inc.Suboxone | $30 | $8,30912 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $6,85711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Kissimmee
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.